Bictegravir-emtricitabine-tenofovir alafenamide (BIC/FTC/TAF; Biktarvy, Gilead) could be a long-term option for older adults with HIV (HIV Med 2022 May 8. doi.org/10.1111/ hiv.13319).
The 96-week study compared 86 men previously taking elvitegravir-cobicistat-FTC-TAF (Stribild, Gilead) or a tenofovir disoproxil fumarate–based regimen with BIC/FTC/TAF. Ultimately, 77 men completed the study. Patients who switched to BIC/FTC/TAF achieved virologic suppression